Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GNRHR | P30968 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935596 | 0.85 | CACNA1G (0.51) | LMNAALDH1A1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL7605695 | 0.80 | CACNA1G (0.42) | ALDH1A1MAPK1MAPTSMN1; SMN2HTR1A | |
| SCHEMBL7607942 | 0.79 | HTR1A (0.58) | LMNAALDH1A1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL17631076 | 0.78 | LMNA (0.56) | LMNAALDH1A1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL6936851 | 0.78 | HTR1A (0.69) | LMNAALDH1A1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL6474949 | 0.77 | HTR1A (0.52) | LMNAALDH1A1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL6934208 | 0.76 | HTR1A (0.59) | LMNAALDH1A1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL25796957 | 0.76 | ALDH1A1 (0.56) | LMNAALDH1A1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL6930796 | 0.76 | DRD2 (0.59) | LMNAALDH1A1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL15540155 | 0.75 | ALDH1A1 (0.55) | LMNAALDH1A1MAPK1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399614-B1 | TREATING NEUROMUSCULAR DYSFUNCTION OF LOWER URINARY TRACT VIA PERIPHERAL OR CENTRAL NERVOUS SYSTEM; SEROTONIN RECEPTOR ANTAGONIST | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-06-04 | — | — | US | claimed |
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMOANY | 2002-12-19 | — | — | US | disclosed |
| US-6399614-B1 | TREATING NEUROMUSCULAR DYSFUNCTION OF LOWER URINARY TRACT VIA PERIPHERAL OR CENTRAL NERVOUS SYSTEM; SEROTONIN RECEPTOR ANTAGONIST | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | NLN, GLS, CPT1B | LMNA 2147/4885ALDH1A1 312/4885MAPK1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.